A5030643739- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Prostate Cancer Treatment and Research
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Radiopharmaceutical Chemistry and Applications
- Cancer Genomics and Diagnostics
- Cancer therapeutics and mechanisms
- Cancer, Lipids, and Metabolism
- Peptidase Inhibition and Analysis
- Pancreatic and Hepatic Oncology Research
- Medical Imaging and Pathology Studies
- Genetic factors in colorectal cancer
- Cancer Diagnosis and Treatment
- RNA modifications and cancer
- Cancer, Hypoxia, and Metabolism
- Lung Cancer Diagnosis and Treatment
- Inflammatory Biomarkers in Disease Prognosis
- Metastasis and carcinoma case studies
- Cancer survivorship and care
- Renal cell carcinoma treatment
- Economic and Financial Impacts of Cancer
- Cancer Research and Treatments
- Ferroptosis and cancer prognosis
European Institute of Oncology
2025
Istituti di Ricovero e Cura a Carattere Scientifico
2025
Azienda Unità Sanitaria Locale Della Romagna
2017-2024
Ospedale Santa Maria
2017-2024
Ospedale "Santa Maria delle Croci" di Ravenna
2020-2024
Chungbuk National University Hospital
2024
Samsung Medical Center
2024
Asan Medical Center
2024
Seoul National University Bundang Hospital
2024
Yonsei University
2024
BackgroundAmivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung cancer (NSCLC).MethodsIn a phase 3, international, randomized trial, we assigned, 2:2:1 ratio, EGFR-mutated (exon 19 deletion L858R), locally metastatic NSCLC to receive amivantamab–lazertinib (in an open-label fashion),...
LBA8010 Background: The phase 3 CheckMate 816 study established neoadjuvant NIVO + chemo as a standard of care for eligible pts with resectable NSCLC. Here, we report the 4-year survival update from this study, representing longest follow-up among all global studies evaluating or perioperative immunotherapy-based treatments. Methods: Adults stage IB (≥ 4 cm)–IIIA (per AJCC v7) NSCLC, ECOG PS ≤ 1, and no known EGFR/ ALK alterations were randomized 1:1 to receive 360 mg Q3W alone cycles,...
Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available non-Asian patients. BEVERLY is an Italian, multicenter, randomized, phase 3 investigating addition as first-line treatment NSCLC.Eligible randomized 1:1 plus or alone. Investigator-assessed PFS and blinded independent centrally reviewed coprimary end points. With 80% power detecting a 0.60 hazard ratio two-sided...
Abstract Purpose: The aims of the present study were to evaluate clinical activity and pharmacodynamic profile novel schedule a single i.v. standard dose cyclophosphamide (CTX) immediately followed by an oral metronomic CTX regimen with celecoxib (CXB) dexamethasone (DEX) in advanced hormone-refractory prostate cancer patients. Experimental Design: Twenty-eight patients (68% docetaxel-resistant) received 500 mg/m2 bolus on day 1 and, from 2, 50 mg/day p.o. plus 200 mg/twice CXB DEX until...
Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into biology. Several biomarkers and signaling pathways have been recognized as conceivable targets for treatment, among them is mesenchymal-epithelial transition/hepatocyte growth factor (c-MET/HGF) axis. Alterations c-MET gene aberrations of MET HGF expression impact on lung prognosis are involved resistance epidermal receptor (EGFR) inhibitors non-small cell (NSCLC) patients harboring activating EGFR...
Lung cancer is the leading cause of deaths. Besides smoking, epidemiological studies have linked female sex hormones to lung in women; however, underlying mechanisms remain unclear. Here we report that receptor activator nuclear factor-kB (RANK), key regulator osteoclastogenesis, frequently expressed primary tumors, an active RANK pathway correlates with decreased survival, and pharmacologic inhibition reduces tumor growth patient-derived xenografts. Clonal genetic inactivation KRasG12D...
Objectives: this study aimed to evaluate the evolution of planned dose distribution quality in two groups breast cancer patients treated with hypofractionated intensity-modulated radiotherapy (IMRT) using Helical TomoTherapy® at our institute 5 years apart. Methods: analysis included cohorts who underwent implant-based immediate reconstruction (IBR) and received post-mastectomy IMRT chest wall infra/supraclavicular lymph nodes, following a 15-fraction regimen (2.67 Gy per fraction). The...
This study aimed at investigating feasibility of programmed death ligand-1 (PD-L1) testing in plasma samples advanced NSCLC patients receiving first-line treatment, assessing whether circulating (c)PD-L1 levels were modified by the therapy and baseline cPD-L1 associated with patients' clinical responses survival outcome.Peripheral blood collected from 16 healthy volunteers 56 newly diagnosed before 12th week during course therapy. The level PD-L1 was measured using human (PD-L1/CD274) ELISA...
Non-small cell lung cancer (NSCLC) is the leading cause of death. Patients eligible for surgery have better overall survival rate than patients who are not eligible. We investigated prognostic value p16 in underwent cancer, association with other factors such as PD-L1 and Ki-67.Expression was evaluated along presence Ki-67 256 NSCLC treated only surgically.Adenocarcinoma prevalent histotype (56%) followed by squamous (29%) differentiation grade 3 most common (60%). detected 83 (30%): low...
// Manolo D'Arcangelo 1 , Armida D'Incecco 2 Claudia Ligorio 3 Stefania Damiani Maurizio Puccetti 4 Sara Bravaccini 5 Luigi Terracciano 6 Chiara Bennati Gabriele Minuti Silvia Vecchiarelli Lorenza Landi Marina Milesi 7 Alberto Meroni 8 Ravaioli Maria Maddalena Tumedei Matteo Incarbone and Federico Cappuzzo AUSL della Romagna, Department of Oncology-Hematology, Ravenna, Italy University Hospital Siena, Medical Oncology Immunotherapy, Center for Immuno-Oncology, Bologna, DIMES, Pathology,...
Background Cancer stem cells represent a population of immature tumor found in most solid tumors. Their peculiar features make them ideal models for studying drug resistance and sensitivity. In this study, we investigated whether cancer isolation vitro sensitivity assay are feasible clinical setting. Methods were isolated from effusions or fresh tissue 23 patients who progressed after standard therapy failure. Specific culture conditions selected that express markers stemness. These exposed...
This is a retrospective analysis on the safety and activity of compassionate Ipilimumab Nivolumab (IPI-NIVO) administered to patients with metastatic Renal Cell Carcinoma (mRCC) intermediate or poor International Metastatic RCC Database Consortium (IMDC) score as first-line regimen. IPI was infused at 1 mg/kg in combination 3 every three weeks for four doses, followed by maintenance (240 480 mg flat dose two weeks, respectively) until disease progression unacceptable toxicity. A total 324...